≥98%HPLC Purity
COAIncluded
USAShipped
NA-931 (Bioglutide) Peptide
First-in-class oral quadruple receptor agonist targeting GLP-1, GIP, glucagon, and IGF-1 receptors simultaneously. Developed by Biomed Industries from a cyclic IGF-1 metabolite fragment. Phase 2 data: -9.2% body weight at 12 weeks via oral administration.
Coming Soon
This compound is currently in our development pipeline. Enter your email to be notified when it becomes available for research purchase.
Quick Facts
| SKU | AC-NA931 |
|---|---|
| Sequence | Cyclic glycine-proline analog (cGP derivative of IGF-1) |
| Purity | Research Grade |
| Physical Form | Oral Tablet/Capsule |
| Storage | Store at room temperature (15-25°C) |
What is NA-931 (Bioglutide)?
NA-931 (Bioglutide) is a first-in-class, orally active quadruple receptor agonist developed by Biomed Industries, Inc. It simultaneously activates four metabolic receptors: GLP-1R, GIPR, GCGR (glucagon), and IGF-1R — making it the only known compound to engage all four pathways in a single molecule.
Unlike injectable peptide agonists (semaglutide, tirzepatide, retatrutide), NA-931 is derived from a cyclic glycine-proline (cGP) fragment of insulin-like growth factor-1 (IGF-1), giving it oral bioavailability. This represents a paradigm shift from injectable peptides to orally administered metabolic therapeutics.
The compound was presented at EASD 2025 and ADA 2025 conferences with Phase 2 data showing -9.2% body weight reduction at 12 weeks via oral dosing — a rate comparable to injectable semaglutide despite the convenience of oral administration.
Quadruple Receptor Mechanism
NA-931 is unique in metabolic pharmacology as it activates four receptors through a single molecular entity:
- GLP-1 Receptor: Appetite suppression via hypothalamic POMC/CART neurons, glucose-dependent insulin secretion, gastric emptying delay — same pathway as semaglutide
- GIP Receptor: Enhanced incretin effect, amplified insulin response, adipose tissue lipid metabolism — same addition as tirzepatide
- Glucagon Receptor: Increased hepatic energy expenditure, fat oxidation, thermogenesis — same addition as retatrutide
- IGF-1 Receptor: The novel fourth target. IGF-1R activation promotes lean body mass preservation, metabolic rate maintenance, and potentially counteracts the muscle loss typically seen with aggressive weight reduction. This is the key differentiator from all existing triple agonists.
Oral bioavailability: The cyclic glycine-proline structure enables gastrointestinal absorption without the need for permeation enhancers (like SNAC used in oral semaglutide). This simplifies formulation and may improve tolerability.
Research & Clinical Studies
Phase 2 Clinical Trial Results
NA-931 Phase 2 trial results presented at major endocrinology conferences:
- Weight loss: -9.2% mean body weight reduction at 12 weeks (oral dosing, once daily)
- Rate of loss: Approximately -0.77% per week — comparable to injectable semaglutide (-0.65%/week in STEP trials) despite oral route
- Oral bioavailability: Confirmed therapeutic plasma levels achieved via oral administration without food restrictions
- Metabolic improvements: Significant reductions in HbA1c, fasting glucose, and triglycerides
- Body composition: Preliminary data suggests better lean mass preservation compared to GLP-1-only agents, attributed to IGF-1R co-activation
- Safety: GI tolerability comparable to existing GLP-1 agonists; no serious adverse events reported
[1] Biomed Industries. NA-931 Phase 2 Success Presented at EASD 2025. Biomed Industries Press Release. PubMed ↗
Comparison: NA-931 vs Semaglutide vs Tirzepatide vs Retatrutide
How NA-931 compares to existing metabolic peptide agonists:
| Feature | Semaglutide | Tirzepatide | Retatrutide | NA-931 |
|---|---|---|---|---|
| Receptors | GLP-1 (1) | GLP-1+GIP (2) | GLP-1+GIP+GCGR (3) | GLP-1+GIP+GCGR+IGF-1R (4) |
| Route | SC injection (oral available) | SC injection | SC injection | Oral only |
| Max weight loss | -14.9% (68wk) | -20.9% (72wk) | -24.2% (48wk) | -9.2% (12wk)* |
| Lean mass | Significant loss | Moderate loss | Some loss | Better preserved (IGF-1R) |
| Frequency | Once weekly | Once weekly | Once weekly | Once daily oral |
*Phase 2 at 12 weeks only — longer trials pending. Rate of loss per week is comparable.
The IGF-1 Receptor Advantage: Lean Mass Preservation
The most innovative aspect of NA-931 is the IGF-1 receptor co-activation. All existing GLP-1 agonists cause 20-40% of weight loss to come from lean body mass (muscle), which is metabolically counterproductive — muscle loss reduces basal metabolic rate, contributing to weight regain after treatment cessation.
IGF-1R activation promotes: skeletal muscle protein synthesis via PI3K/Akt/mTOR pathway, satellite cell activation for muscle maintenance, reduced muscle proteolysis during caloric deficit, and maintenance of basal metabolic rate during weight loss.
If confirmed in Phase 3, this would make NA-931 the first weight loss compound that preferentially reduces fat while preserving muscle — addressing the major criticism of all current anti-obesity pharmacotherapy.
Chemical & Physical Properties
| Name | NA-931 (Bioglutide) |
|---|---|
| Developer | Biomed Industries, Inc. |
| Type | Orally active small molecule (cGP analog, NOT a peptide) |
| Origin | Cyclic glycine-proline fragment of IGF-1 |
| Receptors | GLP-1R + GIPR + GCGR + IGF-1R (quadruple) |
| Route | Oral (once daily) |
| CAS Number | Not publicly disclosed (proprietary) |
| Molecular Formula | Not publicly disclosed (proprietary) |
| Phase | Phase 2 completed |
| Availability | Coming Soon — currently in development pipeline |
Storage & Stability
NA-931 is an oral formulation (tablet/capsule), not a lyophilized peptide. Store at room temperature (15-25°C), protected from moisture and light. No reconstitution required. As an oral small molecule, it has inherently better stability than injectable peptides.
Frequently Asked Questions
Is NA-931 a peptide?
No. NA-931 (Bioglutide) is a small molecule derived from a cyclic glycine-proline fragment of IGF-1, not a peptide. It is orally bioavailable without permeation enhancers — a significant advantage over injectable peptide agonists like semaglutide and tirzepatide.
How does NA-931 compare to retatrutide?
Both are multi-receptor agonists, but NA-931 adds a fourth receptor (IGF-1R) and is oral. Retatrutide is a 39-amino acid injectable peptide targeting 3 receptors (GLP-1/GIP/GCGR). NA-931 targets all 3 plus IGF-1R for lean mass preservation, administered orally once daily.
Why is IGF-1 receptor activation important?
GLP-1 agonists cause 20-40% of weight loss from muscle. IGF-1R activation promotes muscle protein synthesis and satellite cell activation, potentially preserving lean mass during weight loss — addressing the biggest criticism of current anti-obesity drugs.
What phase is NA-931 in?
Phase 2 completed with results presented at EASD 2025 and ADA 2025. Phase 2 showed -9.2% weight loss at 12 weeks via oral dosing. Phase 3 timeline has not been publicly announced.
When will NA-931 be available at AminoCore?
NA-931 is in our development pipeline. Enter your email on the product page to be notified when it becomes available for research purchase. As an oral small molecule, sourcing and quality verification require different processes than peptide products.
For laboratory and research use only. Not intended for human or animal consumption. All product information is derived from published preclinical research and does not constitute medical advice or claims.
